scout
|Articles|May 21, 2013

Mechanism of Action: Sorafenib

Sorafenib is small molecule inhibitor approved for the treatment of primary kidney cancer and advanced primary liver cancer.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME